Granules India Limited, a leading global pharmaceutical company, announced the successful completion of a US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The comprehensive inspection, conducted from August 26 to September 6, 2024, assessed the facility’s adherence to Current Good Manufacturing Practice (cGMP) standards and Pre-Approval Inspection (PAI) requirements. …